Literature DB >> 22905924

Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma.

Shufeng Yang1, Chaoyang Wang, Yujia Zhou, Guojing Sun, Dongmei Zhu, Suning Gao.   

Abstract

The development of Ewing's sarcoma (ES) is a complex process, resulting from interplay between mutations in oncogenes and tumor suppressors, host susceptibility factors, and cellular context. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays important roles in downregulating the T-cell activation. Polymorphisms in the CTLA-4 gene have been shown to be associated with different autoimmune diseases and cancers. The current study evaluated the association of two CTLA-4 gene polymorphisms, -318C/T (rs5742909) and +49G/A (rs231775) with ES in the Chinese population. CTLA-4 polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism in 223 ES cases and 302 age-matched healthy controls. Data were analyzed using the chi-square test. Results showed that prevalence of the CTLA-4 gene +49AA genotype and +49A allele were significantly increased in ES patients compared to controls (odds ratio [OR]=2.03, 95% confidence interval [CI], 1.13-3.66, p=0.018; and OR=1.33, 95%CI, 1.03-1.72, p=0.027). Also, subjects with CA (-318, +49) haplotype had a 1.37-fold increased risk to develop ES (p=0.032). In addition, ES patients with metastasis had higher numbers of +49AA genotype than those with localized cases (OR=2.66, 95%CI, 1.14-6.22, p=0.022). These results indicate that the CTLA-4+49G/A polymorphism is a new risk factor for ES and may affect the prognosis of this cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22905924     DOI: 10.1089/gtmb.2012.0129

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  12 in total

1.  Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.

Authors:  Jianwei Liu; Junli Wang; Weiping Jiang; Yujin Tang
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

2.  Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.

Authors:  Fuyou Zhao; Qiong Wu; Xiusong Dai; Yumei Li; Huaiyong Gan; Ri Wang; Jie Lv; Yuqing Chen
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

3.  Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.

Authors:  Fengbin Yu; Jinhao Miao
Journal:  Tumour Biol       Date:  2013-07-31

4.  A Novel Defined Hypoxia-Related Gene Signature for Prognostic Prediction of Patients With Ewing Sarcoma.

Authors:  Runyi Jiang; Jinbo Hu; Hongfei Zhou; Haifeng Wei; Shaohui He; Jianru Xiao
Journal:  Front Genet       Date:  2022-06-02       Impact factor: 4.772

5.  Upregulation of plasmacytoid dendritic cells in glioma.

Authors:  Rui Wang; Ju-Liang Zhang; Bo Wei; Yu Tian; Zhao-Hui Li; Le Wang; Chao Du
Journal:  Tumour Biol       Date:  2014-06-27

6.  Association between the cytotoxic T-lymphocyte antigen 4-318C/T polymorphism and malignant tumor risk.

Authors:  Taiming Li; Chengdi Wang; Zhenju Ren; Y I Ji; Chang Xu; Bing Xiao; Min Liu
Journal:  Biomed Rep       Date:  2016-05-19

7.  Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies.

Authors:  Lu Wang; Zhiwei Jiang; Hao Qiu; Weifeng Tang; Tanghai Duan; Lixin Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population.

Authors:  Zhengqi Chang; Ruoxian Song; Songfeng Xu; Ming Xu; Xiuchun Yu
Journal:  Tumour Biol       Date:  2014-04-12

9.  Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas.

Authors:  Changchun Fan; Xuechun Zhao; Zhixing Xu
Journal:  Tumour Biol       Date:  2014-09-18

10.  Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Authors:  Clara Benna; Andrea Simioni; Sandro Pasquali; Davide De Boni; Senthilkumar Rajendran; Giovanna Spiro; Chiara Colombo; Calogero Virgone; Steven G DuBois; Alessandro Gronchi; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Oncotarget       Date:  2018-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.